![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma (HGG) harboring an IDH1 mutation.
Lead Product(s): Olutasidenib,Temozolomide
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CONNECT
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Rezlidhia (olutasidenib) is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). It is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptibleisocitrate dehydrogenase-1 (IDH1) mutation.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
REZLIDHIA is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
Rezlidhia (olutasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Optime Care
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 13, 2022
Details:
REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
REZLIDHIA (olutasidenib) is an oral, small molecule, inhibitor of mutated IDH1 designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Rezlidhia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
FT-2102 (olutasidenib), is an oral, small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes,in patients with relapsed/refractory acute myeloid leukemia.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Under the terms of the agreement, Rigel Pharmaceuticals will develop, manufacture and commercialize FT-2102 (olutasidenib), an oral, small molecule inhibitor of mIDH1 being investigated for the treatment of relapsed/refractory acute myeloid leukemia and other malignancies.
Lead Product(s): Olutasidenib,Cytarabine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rigel Pharmaceuticals
Deal Size: $235.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement August 02, 2022
Details:
FT-2102 (Olutasidenib) in combination with Vidaza (Azacitidine) is found to be well-tolerated and, yielded durable complete remission in the first Phase 2 combination trial in patients with the mIDH1 form of acute myeloid leukemia.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
The Phase 1/2 study is a multicenter, open-label, multi-cohort evaluation of the safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of olutasidenib for patients with AML or myelodysplastic syndrome (MDS) with an IDH1 mutation.
Lead Product(s): Olutasidenib
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
FT2102-HEM-101 clinical trial data demonstrate a 30% CR and 3% CRh rate with olutasidenib monotherapy in 123 relapsed or refractory IDH1m AML patients.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: FT-2102
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Oral presentation to highlight clinical data for olutasidenib, an investigational agent, in IDH1 mutant gliomas, including confirmation of blood-brain barrier penetration and preliminary disease control for patients with recurrent, predominantly enhanced glioma.
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
Potent CNS-penetrant, selective IDH1m inhibitor has potential utility in targeting hematologic malignancies, solid tumors and gliomas
Lead Product(s): Olutasidenib,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020